drugset / Trial / NCT05085431
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
NaSingle-groupOpen-labelTreatment
Summary
A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Sjogren's Syndrome
Timeline
- Start
- 2021-11-05
- Primary completion
- 2024-11-05
- Completion
- 2024-11-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19/BCMA CAR T-cells | Cell therapy | 1e+06 cells/kg | Intravenous |
| Subject | CD19/BCMA CAR T-cells | Cell therapy | 4e+06 cells/kg | Intravenous |